EUVIMEDEUVIMED entdecken
Crossref

The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women

Ian Edwin Cock

Pharmacognosy Communications · 17.07.2026 · 16 (3) · 157-158

DOI: 10.5530/pc.2026.3.18 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacognosy Communications, online erschienen am 17.07.2026. Verfasst von Ian Edwin Cock.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Cock, I. E. (2026). The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women. Pharmacognosy Communications, 16(3), 157-158. https://doi.org/10.5530/pc.2026.3.18

Vancouver

Cock IE. The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women. Pharmacognosy Communications. 2026;16(3):157-158. doi:10.5530/pc.2026.3.18

BibTeX
@article{Cock2026,
  author = {Cock, Ian Edwin},
  title = {The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women},
  journal = {Pharmacognosy Communications},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {157--158},
  doi = {10.5530/pc.2026.3.18}
}
Kostenlos starten →